ImmunityBio (NASDAQ:IBRX) Hits New 1-Year High Following Analyst Upgrade

ImmunityBio, Inc. (NASDAQ:IBRX) shares reached a new 52-week high during mid-day trading on Monday after Piper Sandler raised their price target on the stock from $5.00 to $6.00. Piper Sandler currently has a neutral rating on the stock. ImmunityBio traded as high as $8.05 and last traded at $8.05, with a volume of 2369837 shares traded. The stock had previously closed at $7.35.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC raised its holdings in ImmunityBio by 43.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 9,393 shares of the company’s stock valued at $47,000 after acquiring an additional 2,844 shares in the last quarter. Amalgamated Bank grew its position in ImmunityBio by 21.9% in the 4th quarter. Amalgamated Bank now owns 17,752 shares of the company’s stock valued at $89,000 after buying an additional 3,186 shares in the last quarter. Victory Capital Management Inc. boosted its position in shares of ImmunityBio by 25.8% during the 4th quarter. Victory Capital Management Inc. now owns 17,642 shares of the company’s stock valued at $89,000 after purchasing an additional 3,613 shares in the last quarter. Courier Capital LLC boosted its position in shares of ImmunityBio by 33.3% during the 1st quarter. Courier Capital LLC now owns 20,000 shares of the company’s stock valued at $107,000 after purchasing an additional 5,000 shares in the last quarter. Finally, Wealth Effects LLC boosted its position in shares of ImmunityBio by 11.2% during the 4th quarter. Wealth Effects LLC now owns 59,500 shares of the company’s stock valued at $299,000 after purchasing an additional 6,000 shares in the last quarter. 8.58% of the stock is owned by institutional investors and hedge funds.

ImmunityBio Trading Down 11.1 %

The company’s 50-day moving average price is $5.34 and its two-hundred day moving average price is $4.28. The company has a market cap of $5.41 billion, a P/E ratio of -6.89 and a beta of 1.23.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings data on Tuesday, March 19th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). The business had revenue of $0.14 million for the quarter, compared to the consensus estimate of $0.03 million. Equities analysts forecast that ImmunityBio, Inc. will post -0.68 earnings per share for the current year.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies.